Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 29:12:119-136.
doi: 10.2147/BLCTT.S327016. eCollection 2022.

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges

Matthew J Rendo  1 , Jacinth J Joseph  2 , Liem Minh Phan  3 , Christin B DeStefano  4
Affiliations
Review

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges

Matthew J Rendo et al. Blood Lymphat Cancer. .

Abstract

The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric antigen receptor (CAR) T-cell therapies have improved outcomes of patients with hematologic malignancies. B-cell maturation antigen (BCMA) is the current target antigen of choice for most CAR T-cell products under investigation for MM. However, their shortcomings deal with logistical and clinical challenges, including limited availability, manufacturing times, and toxicities. This article provides an overview of recently developed and investigational CAR T-cell therapies for MM, highlighting current evidence and challenges.

Keywords: CAR T-cell; immunotherapy; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The opinions and assertions expressed herein are those of the authors and do not necessarily reflect the official policy or position of the US Air Force or the Department of Defense. None of the authors have any financial or non-financial conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Cytotoxic T-cell.
Figure 2
Figure 2
2nd Generation CAR T-cell Structure.
Figure 3
Figure 3
Autologous CAR T-cell Process.
Figure 4
Figure 4
BCMA Signaling Pathway.
Figure 5
Figure 5
CAR T-cell Fratricide.
See this image and copyright information in PMC

References

    1. National Cancer Institute. Cancer stat facts: myeloma 2021. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed August 22, 2022.
    1. Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2020;38(17):1928–1937. - PMC - PubMed
    1. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024–10028. - PMC - PubMed
    1. Raskov H, Orhan A, Christensen JP, Gogenur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124(2):359–367. - PMC - PubMed
    1. Sharpe AH, Abbas AK. T-cell costimulation–biology, therapeutic potential, and challenges. N Engl J Med. 2006;355(10):973–975. - PubMed